Hodgkin Lymphoma
Conference Coverage
Study confirms higher risk of infection with CB transplant
SALT LAKE CITY—Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher...
Conference Coverage
Expanded UCB product can stand alone
SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...
Conference Coverage
Combo is preferentially active in T-cell lymphomas
LA JOLLA, CA—A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a...
From the Journals
Hodgkin lymphoma survivors are at an increased risk of subsequent ER-negative breast cancer
Subsequent risk of estrogen receptor–negative breast cancer was elevated irrespective of the type of therapy given for Hodgkin lymphoma.
From the Journals
Frontline brentuximab vedotin improved Hodgkin lymphoma outcomes
The study looked at the addition of brentuximab vedotin to chemotherapy in previously untreated patients with stage III or IV classic Hodgkin...
Feature
Gleostine price hike draws fire
Critics say greater generic competition is needed to prevent these types of price jumps.
News
T-cell therapy produces durable responses in rel/ref HL
Engineered T cells can produce durable responses in patients with Epstein Barr virus–positive (EBV+), relapsed/refractory Hodgkin lymphoma (HL),...
News
Survival differences among AYAs with blood cancers
A new report has revealed differences in survival among adolescents and young adults (AYAs) with hematologic malignancies. The report includes...
News
Brentuximab vedotin sBLA receives priority review
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental biologics license application (sBLA) for brentuximab...
News
Research explains why cisplatin causes hearing loss
Researchers have gained new insight into hearing loss caused by cisplatin. By measuring and mapping cisplatin retention in mouse and human inner...
Conference Coverage
A+AVD improves modified PFS in advanced HL
ATLANTA—Phase 3 trial results suggest one 4-drug combination may be more effective than another as frontline treatment for advanced Hodgkin...